Pharmaceutical company PolyPid said today that its D-Plex antibiotic drug reservoir won Qualified Infectious Disease Product status from the FDA.
Under the designation, the Israel-based company’s product will be eligible for priority review, fast-track status and an additional 5 years of market exclusivity.
Get the full story at our sister site, Drug Delivery Business News.
The post PolyPid wins FDA designation for antibiotic drug reservoir appeared first on MassDevice.